Chen Hui Min, Liu Xiao Wei, Sun Rui Juan, Fang Jing Yuan
State Key Laboratory of Oncogene and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute, Shanghai Institute of Digestive Disease, Shanghai, China.
Division of Digestive Disease, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
J Dig Dis. 2015 Aug;16(8):421-30. doi: 10.1111/1751-2980.12274.
Up to 100 trillion bacteria are harbored in the human intestine with a mutualistic and interdependent relationship with the host during a long period of co-evolution. The so-called intestinal microbiota (IM) fulfill important metabolic tasks and the impaired stability may lead to IM-related diseases, including inflammatory bowel disease (IBD), colorectal cancer (CRC), metabolic syndrome (MS), liver diseases, and so on. Here, we review the past and development of IM research in China, including the achievements that Chinese researchers have made both in basic and clinical scientific field. Moreover, we evaluate the contributions of the National Natural Science Foundation of China (NSFC), the 973 National Basic Research Program of China (973 Program), the 863 National High Technology Research and Development Program of China (863 Program), and funds from the public health industry in the field of IM research.
在长期的共同进化过程中，人类肠道中寄居着多达100万亿个细菌，它们与宿主保持着互利共生、相互依存的关系。所谓的肠道微生物群（IM）执行着重要的代谢任务，其稳定性受损可能会导致与IM相关的疾病，包括炎症性肠病（IBD）、结直肠癌（CRC）、代谢综合征（MS）、肝脏疾病等。在此，我们回顾了中国IM研究的过去与发展，包括中国研究人员在基础和临床科学领域所取得的成就。此外，我们评估了中国国家自然科学基金（NSFC）、中国国家重点基础研究发展计划（973计划）、中国国家高技术研究发展计划（863计划）以及公共卫生行业基金在IM研究领域所做的贡献。
